On July 1, the NMPA official website announced that Omecamson (Agluconate Sodium Injection), a Class 1 new drug jointly filed by Omer Pharmaceutical and Xianju Pharmaceutical, has been approved for marketing in China.

Notably, this drug is the only targeted muscle relaxant antagonist in China and one of only two worldwide. Upon approval, it has also become the only patent-protected drug in the muscle relaxant antagonism field globally.

Screenshot from NMPA official website

Omecamson:
Making "Awakening" Safer and More Controllable

Muscle relaxation is one of the three essential elements of general anesthesia surgery, and muscle relaxants are indispensable during such procedures. However, the effects of the muscle relaxant must be reversed promptly after surgery; otherwise, there is a risk of residual neuromuscular blockade, which can lead to respiratory muscle weakness, acute respiratory failure, and even life-threatening complications. Initially known as "Omecamson Sodium," this drug is China's first independently developed intellectual property and the world's second-generation targeted muscle relaxant antagonist. It is a project supported by the National Major New Drug Creation program during the 12th Five-Year Plan, 13th Five-Year Plan, and 2020 periods.

This product is an anesthetic agent primarily used to reverse the effects of non-depolarizing muscle relaxants (such as rocuronium and vecuronium) used during surgery, enabling patients to recover spontaneous breathing and muscle strength more quickly and safely after surgery. Its market benchmark is the global blockbuster drug Sugammadex Sodium. Since its launch, Sugammadex Sodium has achieved global sales exceeding USD 1 billion, becoming a major product in the anesthesia field. Omecamson is designed as a me-better product aiming to provide a clinical option with faster onset and a more favorable side-effect profile.

Omecamson is intended for reversing rocuronium-induced neuromuscular blockade. Results from two Phase III clinical trials head-to-head against the positive control drug Sugammadex Sodium demonstrated that Omecamson has clear efficacy, can rapidly reverse moderate and deep neuromuscular blockade within 3 minutes, and exhibits better stability in pharmacodynamics. It showed significantly lower incidences of recurarization and residual neuromuscular blockade compared to the positive control (P<0.05). Furthermore, Omecamson demonstrated significantly lower incidences of adverse events of special concern (such as allergic reactions, bradycardia, laryngospasm/bronchospasm, etc.) compared to the positive control (P<0.05).

On September 18, 2024, Omecamson's New Drug Application (NDA) submitted to the National Medical Products Administration (NMPA) was successfully accepted. The approval of Omecamson signifies far more than just the launch of a new drug. It represents a revolution in "awakening" and embodies the persistent dedication of Chinese scientists in transforming "impossible challenges" into "China solutions."

Efung Capital:
Anchoring China's Original R&D with Professional Vision

In 2025, Efung Capital made a strategic investment in Omer Pharmaceutical. As one of China's earliest professional investment institutions specializing in the biomedical field, Efung Capital has always been focused on VC/PE investments in the global biopharmaceutical sector. This investment in Omer Pharmaceutical was decisively executed during the critical stage when Omecamson had entered NDA review, leveraging capital to accelerate the launch of China's innovative drugs.

Today, the approval of Omecamson changes more than just the market landscape. For the tens of millions of Chinese patients requiring general anesthesia each year, Omecamson provides a safer guarantee for post-surgical recovery. For the clinical system that has long relied on imported drugs, it offers a domestic alternative with higher accessibility and more controllable costs.

Promoting quality innovative drugs to benefit a broader patient population is at the core of Efung Capital's investment philosophy—ensuring that the power of capital ultimately translates into improved quality of life for every individual. Looking ahead, Efung Capital will continue to drive the industrialization of biotech innovations with capital, helping Chinese hard-tech enterprises build global competitiveness.

END